About Us
History
Silence was formed in 1994 as a publicly traded drug research and development group with an initial focus on immunotherapy.
In 2005, following more than a decade of work, the company transformed itself into a leader in the field of RNAi technology through the acquisition of Atugen AG (now Silence Therapeutics AG). In the years following this transition, Silence has developed and advanced its broad clinical pipeline of RNAi product candidates.
In January 2010, Silence completed a merger with Intradigm Corporation. The merger consolidated Silence's position as a leader in RNAi therapeutics. In particular, it provided access to the Zamore Design Rules patent estate licensed by Intradigm from the University of Massachusetts.